Akeem Gardner
Founder / CEO
Canurta Therapeutics
The startup develops multi-target botanical drugs that utilize rare polyphenols and bioinformatics to create high-quality, clinically active ingredients for treating inflammation and neurological diseases. Their proprietary manufacturing processes enable healthcare professionals to formulate drugs that effectively target the complex physiological factors associated with these conditions.
- Artificial Intelligence
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many neurological and inflammatory diseases are driven by interconnected biological pathways, making them difficult to treat with single-target therapies. Current treatments often provide limited neuroprotection and symptom relief. There is a need for therapies that can address the complex physiological factors associated with these conditions and slow disease progression.
Solution
Canurta Therapeutics develops multi-target botanical drugs using rare polyphenols and AI-driven bioinformatics to create clinically active biopharmaceutical ingredients. Their approach focuses on compounds like cannflavins A & B, which have shown potent anti-inflammatory and neuroprotective properties. Canurta's proprietary PolyKye™ platform accelerates drug discovery by integrating AI and bioinformatics to optimize bioactive compounds. The company's lead candidate, CNR-401, targets multiple key mechanisms involved in ALS, offering a comprehensive solution to combat the disease.
Target Audience
The primary target audience includes patients with neurodegenerative and inflammatory diseases, as well as healthcare professionals seeking innovative treatments for these conditions.
Features
- PolyKye™ platform integrates AI and bioinformatics for drug discovery and optimization
- Patented production methods ensure high purity and potency of therapeutic polyphenols
- Focus on rare polyphenols like cannflavins A & B with enhanced bioavailability
- Blockchain-enabled supply chain for traceability and CMC compliance
- Multi-target approach to address complex disease pathways
- Lead candidate, CNR-401, targets multiple mechanisms in ALS
- Pipeline includes therapies for inflammation (CNR-100) and neurology (CNR-400)